ORPHA:141091
Polyrrhinia
Also known as: Double nose · Polyrhinia
Publications
45
33.4th percentile
Trials
0
Interventional, condition-specific
Researchers
151
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
A rare, major characterized by complete duplication of the nose resulting in two fully developed noses often associated with choanal atresia, causing respiratory distress and necessitating surgical repair.
How rare: How common this is has not been clearly measured.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0015388
- UMLS:C4274730
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
Research-stage checklist from open sources (GenCC, literature, Monarch when enriched, ClinicalTrials.gov). Not a prognosis or care recommendation.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
45 matched papers (16 in last 10 years) Source
- Phenotype characterisedPresent
9 HPO annotations (e.g. Abnormal external nose morphology; Abnormal nasal bone morphology; Orofacial cleft) Source
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialNot found
No matched interventional trial under our ClinicalTrials.gov rules
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
9
Associated phenotypes · MONDO:0015388
- Abnormal external nose morphology
- Abnormal nasal bone morphology
- Orofacial cleft
- Supernumerary naris
- Abnormal skull base morphology
Showing 5 of 9 — open Monarch for the full list.
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
45
45 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
45 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
16 in the last 10 years · medium confidence · 33.4th percentile (publications denominator)
Phrase hits: 45 · MeSH hits: 0
Who's working on it?
151
Distinct author names in 45 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Ghosh P2 papers · 1973Papers in Europe PMC
- 02Humby T2 papers · 2018
Behavioural Genetics Group, Schools of Psychology and Medicine, MRC Centre for Neuropsychiatric Genetics and Genomics, Neuroscience and Mental Health Research Institute, Cardiff University, Cardiff, UK.
Papers in Europe PMC - 03Wang Y2 papers · 2023Papers in Europe PMC
- 04Wilkinson LS2 papers · 2018
Behavioural Genetics Group, Medical Research Council Centre for Neuropsychiatric Genetics and Genomics, Neuroscience and Mental Health Research Institute, Cardiff University, CF24 4HQ United Kingdom.
Papers in Europe PMC - 05Absalan F1 paper · 2024
Medical Faculty, Abadan University of Medical Sciences, Abadan, Iran.
Papers in Europe PMC - 06
- 07Akurati L1 paper · 2006Papers in Europe PMC
- 08
- 09Ayasoufi K1 paper · 2022
Department of Immunology, Mayo Clinic, Rochester, MN, United States.
Papers in Europe PMC - 10
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).
Data as of 11 September 2026 · last trial check 11 September 2026
No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5501 of 7126). Here are the researchers publishing on it.
medium confidence · 38.6th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 40 · after dedupe 40 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 40 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (40)
- isrctn·ISRCTN14787721·No longer recruiting·Safety and effect of cross-linked hyaluronic acid injectable dermal fillers
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN33436648·Recruiting·The study aims to investigate the effect of the level of probiotic K12 content on enhancing children's immunity and reducing the frequency of their occurrence of diseases such as pharyngitis, tonsillitis, and rhinitis
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN37514492·Recruiting·A long-term extension (LTE) study of guselkumab in pediatric participants
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN82171427·Recruiting·Testing gabapentin to treat distorted senses of smell after a viral infection
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN15326567·Recruiting·Defining how antibiotics disrupt lung immune responses in asthma and health
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN11269259·No longer recruiting·A 2-part study to investigate the safety, tolerability and effect of MB272 in healthy volunteers
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN11429329·No longer recruiting·Non-invasive swallow assessment device
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN49654919·No longer recruiting·A study to investigate the safety, tolerability, and concentration in the blood of different dose strengths of ENX-102 in healthy volunteers
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN24865912·No longer recruiting·Evaluate the efficacy, safety and dose-response of S-337395
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN91656864·No longer recruiting·RATIONALE-15: Carriage to assess the protection of new pneumococcal vaccines- PCV15
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN11014449·No longer recruiting·Exploring how oxygen therapy and smart limb exercises can help treat diabetes-related leg artery disease
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN16361887·No longer recruiting·Comparing the effectiveness of a dermo-cosmetic product vs 4% hydroquinone cream for facial melasma treatment: a controlled clinical study
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN36320776·No longer recruiting·Treatment outcomes of two surgical techniques in secondary reconstruction of unilateral cleft lip and ala nasi
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN49040930·No longer recruiting·A long-term study to assess the safety and efficacy of a gel treatment in subjects with Acne Vulgaris
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN29801527·No longer recruiting·A study to characterize nicotine delivery of the JUUL2 electronic nicotine delivery system in adults as compared to a commercially available e-cigarette and combustible cigarette
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN11309776·Recruiting·Antibiotics for uncomplicated lower respiratory tract infection in older adults
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN11462643·No longer recruiting·A study to investigate the effects of IOA-244 in healthy volunteers, including assessment of food effect
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN15384534·No longer recruiting·Modafinil to optimize the performance of cold-stressed sleep-deprived personnel
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN14019493·Recruiting·A randomised, double-blind, parallel group, placebo controlled, trial of Bactek for the prevention of lower respiratory tract infections in preterm infants
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN34837836·No longer recruiting·A study to characterize nicotine delivery of the JUUL2 electronic nicotine delivery system as compared to a commercially available e-cigarette and combustible cigarette
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN16176441·No longer recruiting·A clinical study to evaluate the contents of exhaled breath after use of the JUUL2 electronic nicotine delivery system and conventional cigarettes
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN11835676·No longer recruiting·Efficacy and safety of two hyaluronic acid fillers for the treatment of moderate-to-severe nasolabial folds in a Chinese population
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN82038982·No longer recruiting·A study to investigate the safety, tolerability and effect of RXC008 in healthy volunteers
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN17142179·No longer recruiting·A clinical trial, involving several sites in several countries, with a duration of 12 weeks, where patients, medical doctors and the sponsor do not know the treatment taken by the patient (between one study treatment and another one) with the scope of evaluating the safety of study treatment in comparison with another similar one in subjects with asthma.
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN15169433·No longer recruiting·A phase II clinical trial to investigate the safety, tolerability and efficacy of TransCon CNP, weekly subcutaneous injections, compared with placebo, in infants with achondroplasia
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Polyrrhinia — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Polyrrhinia" OR "Double nose" OR "Polyrhinia"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Polyrrhinia" OR "Double nose" OR "Polyrhinia"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is short or not clearly distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T07:51:20.141Z
